2020
Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation
Dawwas GK, Brensinger CM, Vajravelu RK, Wu Q, Kelly CR, Laine L, Wu GD, Lewis JD. Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation. Clinical Gastroenterology And Hepatology 2020, 20: 806-816.e6. PMID: 33307184, PMCID: PMC8184854, DOI: 10.1016/j.cgh.2020.12.004.Peer-Reviewed Original ResearchConceptsFecal microbiota transplantationIrritable bowel syndromeImmune-mediated diseasesBowel syndromeMyocardial infarctionMicrobiota transplantationRecurrent Clostridioides difficile infectionRecurrent Clostridioides difficileRetrospective cohort studyImmune-mediated conditionsInflammatory bowel diseaseInflammatory bowel syndromeCommercial claims databaseLong-term outcomesClostridioides difficile infectionCohort studyBowel diseaseMicrobiota disturbanceRheumatoid arthritisClaims databaseDifficile infectionHigh riskHigh incidenceGut microbiotaSignificant associationFecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2020, 160: 183-192.e3. PMID: 33011173, PMCID: PMC8034505, DOI: 10.1053/j.gastro.2020.09.038.Peer-Reviewed Original ResearchConceptsClostridioides difficile infectionMicrobiota transplantationSafety profileNational registryProspective real-world studyFull safety profileProspective safety dataBaseline patient characteristicsInflammatory bowel diseaseIrritable bowel syndromeFecal microbiota transplantationLong-term safety outcomesGood safety profileReal-world studyAbdominal painBowel syndromePatient characteristicsReal-world practiceBowel diseaseCDI recurrenceDifficile infectionSafety dataSafety outcomesEffectiveness outcomesSevere symptoms
2015
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology 2015, 149: 223-237. PMID: 25982290, PMCID: PMC4755303, DOI: 10.1053/j.gastro.2015.05.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsFecal microbiota transplantationClostridium difficile infectionGut microbiotaRecurrent Clostridium difficile infectionInflammatory bowel diseaseIrritable bowel syndromeTreatment of patientsRobust safety dataLong-term safetyBowel diseaseBowel syndromeMetabolic syndromeMicrobiota transplantationDifficile infectionSafety dataTherapeutic efficacyOrgan systemsDisease statesHuman gutSyndromePossible roleDiseaseEfficacyMicrobiotaTreatment
2013
What Is the Value of a Food and Drug Administration Investigational New Drug Application for Fecal Microbiota Transplantation to Treat Clostridium difficile Infection?
Hecht GA, Blaser MJ, Gordon J, Kaplan LM, Knight R, Laine L, Peek R, Sanders ME, Sartor B, Wu GD, Yang VW. What Is the Value of a Food and Drug Administration Investigational New Drug Application for Fecal Microbiota Transplantation to Treat Clostridium difficile Infection? Clinical Gastroenterology And Hepatology 2013, 12: 289-291. PMID: 24148361, DOI: 10.1016/j.cgh.2013.10.009.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements